Six-year CEO tenure ends as Anita James takes interim MVP role

CFO takes control as MVP begins CEO search

Medical Developments International (ASX:MVP) is changing chief executives just days after reporting a stronger FY26, with Brent MacGregor stepping down and CFO Anita James taking the interim role from 15 October. MacGregor will remain available in an advisory capacity until 15 November, giving the business a defined handover period while the board searches for a permanent CEO.

MacGregor said he was returning to North America, where his family is based, after six years leading MVP. He said the company had made progress in expanding Penthrox adoption and securing regulatory approvals, and would continue supporting James and the board during the transition.

Leadership change follows improved Penthrox performance

The timing places the succession question alongside a more encouraging operating story. MVP’s FY26 profit and cashflow improved, with the company reporting a return to EBIT profitability, stronger Penthrox volumes and free cash flow of $4.2 million. Those results also highlighted the unevenness of the portfolio: Respiratory revenue declined during the year.

Chair Mark Fladrich said MacGregor had helped grow Penthrox revenue, improve margins, strengthen cash generation and secure regulatory milestones, including a paediatric indication approval in the UK and European Union. The announcement does not provide new financial guidance or quantify any expected financial effect from the executive transition.

Permanent succession becomes the next execution test

James brings internal knowledge to the interim position, including an understanding of MVP’s financial position and capital allocation priorities, according to the board. Her remuneration will remain unchanged from the terms disclosed in the 2026 annual report.

For shareholders, the immediate issue is less the mechanics of the handover than what the permanent appointment says about the company’s next phase. MVP has positioned Penthrox expansion and recent approvals as foundations for growth; the board must now find a leader capable of carrying that strategy forward without interrupting the operational momentum MacGregor leaves behind.